TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24388010

Group type: EXPERIMENTAL
Intervention: 500 index of reactivity (IR) tablets
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: 300 index of reactivity (IR) tablets
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study: 22475306

Group type: EXPERIMENTAL
Intervention: Honey
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: HOPE
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (benzocaine gel)
Number of subjects: 90
Study: 20447832

Group type: EXPERIMENTAL
Intervention: CABG+CRT
Number of subjects: 178

Group type: COMPARATOR
Intervention: CABG
Number of subjects: 178
Study: 17050549

Group type: EXPERIMENTAL
Intervention: Bilateral cystectomy (experimental group, n=15)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oophorectomy plus controlateral cystectomy (control group, n=17)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Bilateral cystectomy (experimental group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Oophorectomy plus controlateral cystectomy (control group)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 32
Study: 15621324

Group type: EXPERIMENTAL
Intervention: Robotic-assisted walking (Lokomat)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treadmill walking
Number of subjects: 0
Study: 12402450

Group type: EXPERIMENTAL
Intervention: 0.5% timolol aqueous solution
Number of subjects: 24

Group type: COMPARATOR
Intervention: 0.1% timolol hydrogel
Number of subjects: 24
Study: 10465182

Group type: EXPERIMENTAL
Intervention: Transdermal oestradiol 80 microg with continuous oral norethisterone 1 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8652243

Group type: EXPERIMENTAL
Intervention: Mepacrine chloride
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 30
Study: 2190476

Group type: EXPERIMENTAL
Intervention: Roux‐Y gastrojejunostomy
Number of subjects: 121

Group type: COMPARATOR
Intervention: Gastroduodenostomy (Billroth I)
Number of subjects: 121
Study: 373393

Group type: EXPERIMENTAL
Intervention: Potassium chloride (1500 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Spironolactone (50 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Amiloride (5 mg daily)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triamterene (75 mg daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (50 mg daily)
Number of subjects: 40
Study: 31042551

Group type: EXPERIMENTAL
Intervention: bucindolol
Number of subjects: 267

Group type: COMPARATOR
Intervention: metoprolol
Number of subjects: 267
Study: 28289112

Group type: EXPERIMENTAL
Intervention: Brief intervention conducted by general practitioners (FRAMES model)
Number of subjects: 261

Group type: COMPARATOR
Intervention: Routine care
Number of subjects: 261
Study: 25933559

Group type: EXPERIMENTAL
Intervention: Mesh fixation with metal non-absorbable tackers (Group I)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No fixation of mesh (Group II)
Number of subjects: 63
Study: 23535872

Group type: EXPERIMENTAL
Intervention: PGS singletons
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: PGS twins
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control singletons
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control twins
Number of subjects: 113
Study: 21861935

Group type: EXPERIMENTAL
Intervention: Hylan G-F 20 injections (4 courses of 3 × 2.0 ml at 6 month intervals)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Usual care for knee OA without injections
Number of subjects: 78
Study: 19718004

Group type: EXPERIMENTAL
Intervention: Periodontal therapy combined with tacrolimus
Number of subjects: 16

Group type: COMPARATOR
Intervention: Oral hygiene instructions only (Control)
Number of subjects: 16
Study: 17230289

Group type: EXPERIMENTAL
Intervention: 50 IU Syntocinon (in 30 ml N saline)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: 800 mcg misoprostol (in 30 ml N saline)
Number of subjects: 54

Group type: COMPARATOR
Intervention: 30 ml N saline (control)
Number of subjects: 54
Study: 16083168

Group type: EXPERIMENTAL
Intervention: Lomefloxacin 0.3%
Number of subjects: 40

Group type: COMPARATOR
Intervention: Fortified cefazolin and gentamicin
Number of subjects: 40
Study: 11561233

Group type: EXPERIMENTAL
Intervention: Core suture methods (Kessler, modified Kessler, Savage, Lee, augmented Becker, or Tsuge finished with a circumferential running suture)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Repairs without the core suture (including unrepaired tendons)
Number of subjects: 118
Study: 9776437

Group type: EXPERIMENTAL
Intervention: CYP2D6*1/CYP2D6*1 (homozygous)
Number of subjects: 36

Group type: COMPARATOR
Intervention: CYP2D6*1/CYP2D6*4 (heterozygous)
Number of subjects: 36
Study: 7821456

Group type: EXPERIMENTAL
Intervention: Oral tetracycline (250 mg twice daily for 12 weeks)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral tetracycline (250 mg twice daily for 12 weeks) and topical prednisolone (for the first 7 days)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard treatment (Control group A)
Number of subjects: 30
Study: 2839579

Group type: EXPERIMENTAL
Intervention: Intranasal sprays of recombinant beta serine interferon (rIFN‐beta ser)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Daily nasal drops of rIFN‐beta ser
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Low-dose rIFN‐beta ser
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: High-dose rIFN‐beta ser
Number of subjects: 120
Study: 31258916

Group type: EXPERIMENTAL
Intervention: Sleep protocol (n=26)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Usual care (n=30)
Number of subjects: 56
Study: 27779917

Group type: EXPERIMENTAL
Intervention: Use of provided checklists during appointments
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not asked to use checklists but had them available
Number of subjects: 0
Study: 26053242

Group type: EXPERIMENTAL
Intervention: Carpal Tunnel Release (CTR)
Number of subjects: 30
Study: 23531037

Group type: EXPERIMENTAL
Intervention: Hepcidin-25
Number of subjects: 49

Group type: COMPARATOR
Intervention: Urine hepcidin-1 in megalin-deficient mice
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Hepcidin-25 post-cardiac surgery
Number of subjects: 49
Study: 21697156

Group type: EXPERIMENTAL
Intervention: Digora (PSP system) and film
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: VistaScan (PSP system) and film
Number of subjects: 110

Group type: COMPARATOR
Intervention: Film
Number of subjects: 110
Study: 20128295

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) applied at 2 Hz/100 Hz, 4-6 V to specific acupuncture points 30 min before colonoscopy.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no electroacupuncture).
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA).
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electroacupuncture (EA) and Control group.
Number of subjects: 60
Study: 18200775

Group type: EXPERIMENTAL
Intervention: Nifedipine (twice-daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study: 14741066

Group type: EXPERIMENTAL
Intervention: Extended-release lovastatin (20 mg)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Immediate-release lovastatin (20 mg)
Number of subjects: 179
Study: 11716446

Group type: EXPERIMENTAL
Intervention: Oral cyclophosphamide 50 mg/day and tamoxifen 20 mg/day plus 1‐hexylcarbamoyl‐5‐fluorouracil 300 mg/day for 2 years
Number of subjects: 785

Group type: COMPARATOR
Intervention: Oral cyclophosphamide 50 mg/day and tamoxifen 20 mg/day for 2 years
Number of subjects: 785
Study: 9159449

Group type: EXPERIMENTAL
Intervention: Ultrasonographic findings in karyotypically normal pregnancies
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Ultrasonographic findings in pregnancies with abnormal karyotypes
Number of subjects: 137

Group type: COMPARATOR
Intervention: Comparison of ultrasonographic findings between normal and abnormal karyotypes
Number of subjects: 137
Study: 8503964

Group type: EXPERIMENTAL
Intervention: Birth center care
Number of subjects: 1230

Group type: COMPARATOR
Intervention: Standard obstetric care
Number of subjects: 1230
Study: 3029258

Group type: EXPERIMENTAL
Intervention: Adrenaline (3 micrograms/min) i.v. for 150 min
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Synthetic ovine corticotrophin-releasing factor-41 (oCRF-41; 25 micrograms)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Synthetic ovine corticotrophin-releasing factor-41 (oCRF-41; 50 micrograms)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 6
Study: 29720328

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthwash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluorine mouthwash
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Essential oils mouthwash
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no specific mouthwash mentioned)
Number of subjects: 0
Study: 26626823

Group type: COMPARATOR
Intervention: Normal energy food foam (NEF1, 280 kJ/400 mL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Very low energy food foam (VLEF, 36 kJ/400 mL)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Alternative normal energy foam (NEF2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Alternative normal energy foam (NEF3)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: All foams
Number of subjects: 72
Study: 24814695

Group type: EXPERIMENTAL
Intervention: Nasal irrigator (Group A)
Number of subjects: 1134

Group type: EXPERIMENTAL
Intervention: Homemade nasal irrigation connector combined with enemator (Group B)
Number of subjects: 1134

Group type: COMPARATOR
Intervention: Nasal sprayer (Group C)
Number of subjects: 1134
Study: 23136318

Group type: EXPERIMENTAL
Intervention: GEL (lubricant gel use before speculum insertion)
Number of subjects: 400

Group type: COMPARATOR
Intervention: NO GEL (no lubricant gel use before speculum insertion)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: GEL (lubricant gel use) in premenopausal women
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: GEL (lubricant gel use) in postmenopausal women
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: GEL (lubricant gel use) in women of reproductive age
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Cytological interpretations of the Papanicolaou test specimens
Number of subjects: 400
Study: 20032194

Group type: EXPERIMENTAL
Intervention: Vabicaserin (oral administration)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: In vitro (CO2-enriched environment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vabicaserin metabolism
Number of subjects: 0
Study: 18589314

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 177

Group type: COMPARATOR
Intervention: Hysterectomy
Number of subjects: 177
Study: 15750171

Group type: EXPERIMENTAL
Intervention: Multiple-time graphical analysis of 18F-fluoro-L-DOPA uptake constant (K(i), min(−1)) in basal ganglia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: SPM analysis of 18F-fluoro-L-DOPA uptake constant (K(i), min(−1)) in basal ganglia
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: All-brain SPM analysis
Number of subjects: 35
Study: 12585100

Group type: EXPERIMENTAL
Intervention: Kidney tonifying method
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study: 10731009

Group type: EXPERIMENTAL
Intervention: Creatine (Cr) supplementation
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 9147856

Group type: EXPERIMENTAL
Intervention: Clodronate 3 x 800 mg orally
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no clodronate)
Number of subjects: 22
Study: 1491771

Group type: EXPERIMENTAL
Intervention: Cyclic hormone replacement therapy with conjugated estrogens (0.625 mg and 1.25 mg) and progestagens (medroxyprogesterone acetate or medrogestone)
Number of subjects: 363
Study: 3161007

Group type: EXPERIMENTAL
Intervention: Cefaclor
Number of subjects: 2026

Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 2026
Study: 30453972

Group type: EXPERIMENTAL
Intervention: CID+ patients (≥100 mL decrease in FEV1, ≥4-unit increase in SGRQ score, or moderate/severe exacerbation)
Number of subjects: 4312

Group type: EXPERIMENTAL
Intervention: CID+ patients
Number of subjects: 4312
Study: 26646197

Group type: EXPERIMENTAL
Intervention: Family Check-Up (FCU) intervention
Number of subjects: 0
Study: 25144818

Group type: EXPERIMENTAL
Intervention: WE + ILP
Number of subjects: 69

Group type: COMPARATOR
Intervention: WE
Number of subjects: 69
Study: 22520669

Group type: EXPERIMENTAL
Intervention: 3-monthly GP visits (intensive care)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Usual GP care (opportunistic care)
Number of subjects: 1200
Study: 20479407

Group type: EXPERIMENTAL
Intervention: Paclitaxel added to adjuvant doxorubicin plus cyclophosphamide (AC) chemotherapy
Number of subjects: 1581

Group type: COMPARATOR
Intervention: AC chemotherapy alone
Number of subjects: 1581
Study: 18752330

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV) 10 mg
Number of subjects: 171
Study: 16042933

Group type: EXPERIMENTAL
Intervention: Single high-fluence purpuric pass
Number of subjects: 9

Group type: COMPARATOR
Intervention: Four low-fluence subpurpuric passes
Number of subjects: 9
Study: 14521275

Group type: EXPERIMENTAL
Intervention: Standard EEG
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Standard EEG with focal epileptiform activity
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: EEG with sleep deprivation
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Routine EEG
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Neuroradiological examinations
Number of subjects: 157
Study: 10926637

Group type: EXPERIMENTAL
Intervention: 7 g/day of pyruvate
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 8874117

Group type: COMPARATOR
Intervention: Mask CPAP for 20 min (group A, n = 24)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Volume expansion with 9 ml of 3 ml albumin, 3 ml glucose, and 3 mEq of sodium bicarbonate (group B, n = 24)
Number of subjects: 103

Group type: COMPARATOR
Intervention: Volume expansion with 4.5 ml albumin and 4.5 ml glucose (group C, n = 14)
Number of subjects: 103
Study: 31581591

Group type: EXPERIMENTAL
Intervention: Whey protein supplement enriched with leucine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 28
Study: 29075885

Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 165

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 165
Study: 26721653

Group type: EXPERIMENTAL
Intervention: Aspirin treatment
Number of subjects: 400

Group type: COMPARATOR
Intervention: Enoxaparin replacement
Number of subjects: 400
Study: 24467672

Group type: EXPERIMENTAL
Intervention: Radiofrequency vessel-sealing system (LF1212 group)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Clamp-crushing technique (Kelly group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 22385885

Group type: EXPERIMENTAL
Intervention: 10mg fluvastatin/20mg valsartan daily for 30 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 18344726

Group type: EXPERIMENTAL
Intervention: Imipramine treatment for 6 weeks
Number of subjects: 112
Study: 16826400

Group type: EXPERIMENTAL
Intervention: Psilocybin (30 mg/70 kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Methylphenidate hydrochloride (40 mg/70 kg)
Number of subjects: 30
Study: 14655885

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) - 3 sessions of 3000 shock waves/session at 0.2 mJ/mm2, weekly intervals
Number of subjects: 47

Group type: COMPARATOR
Intervention: Conventional conservative treatment (iontophoresis with diclofenac and oral NSAID) for 12 weeks followed by ESWT protocol
Number of subjects: 47
Study: 11035668

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 2,000 microg via metered‐dose inhaler for 5 consecutive days
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9120655

Group type: EXPERIMENTAL
Intervention: Nurse case manager intervention
Number of subjects: 478

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 478
Study: 1570496

Group type: EXPERIMENTAL
Intervention: diclofenac/misoprostol
Number of subjects: 339

Group type: COMPARATOR
Intervention: diclofenac/placebo
Number of subjects: 339
Study: 2580176

Group type: EXPERIMENTAL
Intervention: Acute angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronic angiotensin-converting enzyme (ACE) inhibition
Number of subjects: 0
Study: 30203681

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal rings with 300 µg 17β-estradiol and 75-125 µg/day of etonogestrel (ENG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contraceptive vaginal rings with 300 µg 17β-estradiol and 500-900 µg/day of nomegestrol acetate (NOMAC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ENG-E2 125/300 µg/day group
Number of subjects: 0

Group type: COMPARATOR
Intervention: NuvaRing (ENG/ethinylestradiol 120/15 µg)
Number of subjects: 0
Study: 27472648

Group type: EXPERIMENTAL
Intervention: Standard cancer care plus systematic EPC (n = 107)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Standard cancer care plus on-demand EPC (n = 100)
Number of subjects: 207
Study: 24874006

Group type: EXPERIMENTAL
Intervention: Web‐based Solution‐Focused Brief Therapy (SFBT) intervention (n=131)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Waiting list control group (n=132)
Number of subjects: 263
Study: 23327035

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Group D) - loading dose of 1 microg/kg IV over ten minutes, followed by continuous infusion at 0.5 microg/kg/hr throughout surgery
Number of subjects: 54

Group type: COMPARATOR
Intervention: Saline (Group S) - same volume as dexmedetomidine infusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Final BIS number and sevoflurane concentrations
Number of subjects: 54
Study: 20573787

Group type: EXPERIMENTAL
Intervention: 35 micro g Se as l-selenomethionine
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: 21 micro g Se as l-selenomethionine
Number of subjects: 98

Group type: COMPARATOR
Intervention: 0 micro g Se (placebo)
Number of subjects: 98
Study: 18043579

Group type: EXPERIMENTAL
Intervention: Dose-intensive epirubicin and cyclophosphamide with filgrastim and progenitor cell support (DI-EC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-dose anthracycline-based chemotherapy (SD-CT)
Number of subjects: 0
Study: 16897413

Group type: EXPERIMENTAL
Intervention: Integrated Assertive Community Treatment (IACT)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Assertive Community Treatment only (ACTO)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: IACT
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: ACTO
Number of subjects: 149
Study: 12827120

Group type: EXPERIMENTAL
Intervention: EMLA cream with heat for 20 minutes
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: EMLA cream for 60 minutes without heat
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo with heat
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo without heat
Number of subjects: 76
Study: 10917988

Group type: EXPERIMENTAL
Intervention: IPC(foot)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IPC(calf)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: IPC(foot+calf)
Number of subjects: 45
Study: 8863764

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1893291

Group type: EXPERIMENTAL
Intervention: Synthetic human calcitonin 0.25 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Synthetic human calcitonin 0.125 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 6380896

Group type: EXPERIMENTAL
Intervention: Nitrogen mustard (0.1 mg/kg body weight) administered in 3 intravenous bolus injections over 3-5 weeks
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (4 cases)
Number of subjects: 33
Study: 28750588

Group type: EXPERIMENTAL
Intervention: Strength training of shoulder/neck muscles for ten weeks using elastic resistance bands.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ergonomic and posture correction (control group).
Number of subjects: 60
Study: 27077354

Group type: EXPERIMENTAL
Intervention: Text messaging group
Number of subjects: 1393
Study: 24128168

Group type: EXPERIMENTAL
Intervention: Direct refluxing technique
Number of subjects: 102

Group type: COMPARATOR
Intervention: SLET technique
Number of subjects: 102
Study: 21993365

Group type: EXPERIMENTAL
Intervention: Medication Event Monitoring System (MEMS) and pill count
Number of subjects: 470

Group type: COMPARATOR
Intervention: Pill count alone (control group)
Number of subjects: 470

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 470

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 470
Study: 20859153

Group type: EXPERIMENTAL
Intervention: Continuous wound infusion below the fascia using ropivacaine and ketoprofene
Number of subjects: 56

Group type: COMPARATOR
Intervention: Continuous wound infusion above the fascia using ropivacaine and ketoprofene
Number of subjects: 56
Study: 18408049

Group type: EXPERIMENTAL
Intervention: Nebulised furosemide 40 mg
Number of subjects: 15

Group type: COMPARATOR
Intervention: Nebulised 0.9% saline
Number of subjects: 15

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 15
Study: 16160802

Group type: EXPERIMENTAL
Intervention: Strict metabolic control with insulin administration (fasting glucose levels to 90 mg/dl and 130 mg/dl postprandially)
Number of subjects: 875

Group type: COMPARATOR
Intervention: Normal glucose tolerance (NGT)
Number of subjects: 875
Study: 14559315

Group type: EXPERIMENTAL
Intervention: Urban diet
Number of subjects: 33

Group type: COMPARATOR
Intervention: Rural diet
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Both diets
Number of subjects: 33
Study: 11219953

Group type: EXPERIMENTAL
Intervention: Honey Laminolact (therapeutic/prophylactic dragee)
Number of subjects: 44